Patents Assigned to Pharma Mar, S.A.
  • Antitumoral Compounds
    Publication number: 20100280108
    Abstract: A compound of general formula (I) wherein, R11, R12, R13, R14, R15, W, Y, R1, R2, R3, R4, R5, and R6 take various meanings for use in the treatment of cancer.
    Type: Application
    Filed: December 19, 2008
    Publication date: November 4, 2010
    Applicant: Pharma Mar, S.A.
    Inventors: Alberto Rodriguez Vicente, Maria Garranzo García-Ibarrola, Carmen Murcia Pérez, Francisco Sánchez Sancho, Maria del Carmen Cuevas Marchante, Cristina Mateo Urbano, Isabel Digón Juárez
  • Prognostic Molecular Markers for ET-743 Treatment
    Publication number: 20100267732
    Abstract: The present invention relates to the use of ecteinascidin 743 in human patients having certain molecular markers profile which has been associated with the outcome of ET-743 chemotherapy. In particular, the invention relates to the use of ecteinascidin 743 in patients having high expression levels of XPG mRNA or protein and/or having a “wild type” genotype for Asp1104His SNP of XPG gene.
    Type: Application
    Filed: October 20, 2008
    Publication date: October 21, 2010
    Applicant: PHARMA MAR, S.A.
    Inventors: Rafael Rosell Costa, Miguel Tarón Roca, Nerea Martínez Magunacelaya, Ana Díez Rodríguez, José Mª Jimeno Donaque, Juan Carlos Tercero López
  • Improved Antitumoral Treatments
    Publication number: 20100240595
    Abstract: The present invention relates to combinations of Aplidine with Gemcitabine, and the use of these combinations in the treatment of cancer.
    Type: Application
    Filed: October 20, 2008
    Publication date: September 23, 2010
    Applicant: PHARMA MAR ,S.A.
    Inventors: Giuseppe Longo Sorbello, Pravin Jaiprakash Mishra, Prasun Jaiprakash Mishra, Joseph Rocco Bertino, Debabrata Banerjee, José Maria Jimeno Donaque
  • Synthesis of naturally occurring ecteinascidins and related compounds
    Patent number: 7795260
    Abstract: Ecteinascidin compounds with a quinone ring for ring E are active as anti-cancer agents. Related processes and compounds are provided.
    Type: Grant
    Filed: November 19, 2008
    Date of Patent: September 14, 2010
    Assignee: Pharma Mar, S.A.
    Inventors: Valentin Martinez Barrasa, Pilar Gallego, Carmen Cuevas, Simon Munt, Ignacio Manzanares, Roberto Menchaca, Natividad Rodriguez, Alberto Rodriguez
  • Antitumoral Treatments
    Publication number: 20100226919
    Abstract: The present invention relates to combinations of PM02734 with EGFR tyrosine kinase inhibitors, and the use of these combinations in the treatment of cancer.
    Type: Application
    Filed: October 17, 2008
    Publication date: September 9, 2010
    Applicants: Pharma Mar, S.A., ALBERT EINSTEIN COLLEGE OF MEDICINE OF YESHIVA UNIVERSITY
    Inventors: Román Pérez-Soler, Yi-He Ling, José Maria Jimeno Donaque, Yi-Yu Zou
  • Variolin derivatives and their use as antitumor agents
    Patent number: 7772241
    Abstract: Variolin derivatives of formula (5) are provided, wherein the substituent groups defined by X2, R1, R2, R3, R6, R7, and R12 are each independently selected from the group consisting of H, OH, OR?, SH, SR?, SOR?, SO2R?, NO2, NH2, NHR?, N(R?)2, NHCOR?, NHSO2R?, CN, halogen, ?O, C(?O)H, C(?O)R?, CO2H, CO2R?, carboxyalkyl, C1-C12 alkyl, C2-C12 alkenyl, C2-C12 alkynyl, substituted or unsubstituted aryl, substituted or unsubstituted aralkyl and substituted or unsubstituted heteroaromatic; wherein each of the R? groups is independently selected from the group consisting of H, OH, SH, NO2, NH2, CN, halogen, ?O, C(?O)H, C(?O)CH3, CO2H, CO2CH3, C1-C12 alkyl, C2-C12 alkenyl, C2-C12 alkynyl, aryl, aralkyl and heteroaromatic; wherein the pairs of groups of R1 and R2, R2 and R3, R3 and R12, R12 and R6, or R6 and R7 may be joined into a carbocyclic or heterocyclic ring system.
    Type: Grant
    Filed: January 7, 2009
    Date of Patent: August 10, 2010
    Assignee: Pharma Mar S.A.
    Inventors: Modesto Remuinan, Juan Jose Gonzalez, Carlos Del Pozo, Andres Francesh, Carmen Cuevas, Simon Munt, Ignacio Manzanares, Regan James Anderson, Jonathan Charles Morris
  • Synthesis of naturally occurring ecteinascidins and related compounds
    Patent number: 7767659
    Abstract: Ecteinascidin compounds with a quinone ring for ring E are active as anti-cancer agents. Related processes and compounds are provided.
    Type: Grant
    Filed: February 4, 2003
    Date of Patent: August 3, 2010
    Assignee: Pharma Mar, S.A.
    Inventors: Valentin Martinez Barrasa, Pilar Gallego, Carmen Cuevas, Simon Munt, Ignacio Manzanares, Roberto Menchaca, Natividad Rodriguez, Alberto Rodriguez
  • Ecteinascidin analogs for use as antitumour agents
    Patent number: 7763615
    Abstract: Derivatives of ecteinascidin 736 of general formula (I) wherein the groups R1, R2, R3, R4 and R5 are each independently selected from the group consisting of H, OH, OR?, SH, SR?, SOR?, SO2R?, C(?O)R?, C(?O)OR?, NO2, NH2, NHR?, N(R?)2, NHC(O)R?, CN, halogen, ?O, substituted or unsubstituted C1-C25 alkyl, substituted or unsubstituted C2-C18 alkenyl, substituted or unsubstituted C2-C18 alkynyl, substituted or unsubstituted aryl, substituted or unsubstituted heterocyclic; wherein X is independently selected of OR?, CN, (?O), or H; wherein each of the R? groups is independently selected from the group consisting of H, OH, NO2, NH2, SH, CN, halogen, ?O, C(?O)H, C(?O)CH3, CO2H, substituted or unsubstituted C1-C25 alkyl, substituted or unsubstituted C2-C18 alkenyl, substituted or unsubstituted C2-C18 alkynyl, substituted or unsubstituted aryl; wherein m is 0, 1 or 2; and wherein n is 0, 1, 2, 3, or 4, and their use as antitumoral agent.
    Type: Grant
    Filed: August 6, 2002
    Date of Patent: July 27, 2010
    Assignee: Pharma Mar, S.A.
    Inventors: Pilar Gallego, Carmen Cuevas, Simon Munt, Ignacio Manzanares, Valentin Martinez
  • Antitumoral derivatives of ET-743
    Patent number: 7759345
    Abstract: Derivatives of Et-743 or Et-770 or Et-729 are provided. The derivatives are of the general formula (Ia) wherein the substituent groups take various permitted meanings.
    Type: Grant
    Filed: July 17, 2002
    Date of Patent: July 20, 2010
    Assignee: Pharma Mar, S.A.
    Inventors: Valentin Martinez, Maria Flores, Pilar Gallego, Carmen Cuevas, Simon Munt, Ignacio Manzanares
  • Kahalalide compositions
    Patent number: 7683028
    Abstract: The present invention is directed to new kahalalide antitumoral compounds, in particular to analogs of kahalalide F, useful as antitumoral, antiviral, and antifungal agents.
    Type: Grant
    Filed: January 25, 2008
    Date of Patent: March 23, 2010
    Assignee: Pharma Mar, S.A.U.
    Inventors: Glynn Thomas Faircloth, Maria del Carmen Cuevas Marchante
  • Synthetic methods for aplidine and new antitumoral derivatives, methods of making and using them
    Patent number: 7678765
    Abstract: The invention relates to aplidine derivatives of the general formula: which are useful for the treatment of tumors.
    Type: Grant
    Filed: April 20, 2007
    Date of Patent: March 16, 2010
    Assignee: Pharma Mar, S.A.
    Inventors: Ignacio Rodriguez, Concepción Polanco, Felix Cuevas, Paloma Mandez, Carmen Cuevas, Pilar Gallego, Simon Munt, Ignacio Manzanares
  • ANTITUMORAL DIHYDROPYRAN-2-ONE COMPOUNDS
    Publication number: 20100048690
    Abstract: Antitumoral compounds obtained from a porifera, of the family Raspailiidae, genus Lithoplocamia, species lithistoides, and derivatives thereof are provided.
    Type: Application
    Filed: June 15, 2007
    Publication date: February 25, 2010
    Applicant: PHARMA MAR, S.A.
    Inventors: Ma Jesus Martin Lopez, Laura Coello Molinero, Jose Fernando Reyes Benitez, Alberto Rodriguez Vicente, Maria Garranzo Garcia-Ibarrola, Carmen Murcia Perez, Andres Francesch Solloso, Francisco Sanchez Sancho, Maria del Carmen Cuevas Marchante, Rogelio Fernandez Rodriguez
  • Indole Derivatives as Antitumoral Compounds
    Publication number: 20100048596
    Abstract: Antitumoural compounds of general formula (I); wherein Ar is an heterocyclic group of formula (a) and R1, R2, R3, R4, R5, R6, R7, n and the dotted line take permitted meanings can be obtained from a tunicate of the family Polyclinidae, genus Aplidium, species cyaneum, and the invention further provides derivatives thereof.
    Type: Application
    Filed: November 13, 2006
    Publication date: February 25, 2010
    Applicant: Pharma Mar, S.A.
    Inventors: Jose Fernando Reyes Benitez, Andrés Francesch Solloso, Carmen Cuevas Marchante, Marta Altuna Urquijo, Daniel Pla Queral, Mercedes Alvarez Domingo, Fernando Albericio Palomera
  • Use of Aplidine for the Treatment of Pancreatic Cancer
    Publication number: 20100041594
    Abstract: Aplidine is active against cancer of the pancreas, including metastatic pancreatic cancer.
    Type: Application
    Filed: October 23, 2009
    Publication date: February 18, 2010
    Applicant: Pharma Mar, S.A.
    Inventors: Ramón Mangues, Rubén Henriquez, José Jimeno
  • Anticancer Treatments
    Publication number: 20100009906
    Abstract: A method of treating the human body for cancer comprises administering an effective therapeutic amount of docetaxel in combination with an effective therapeutic amount of ET-743.
    Type: Application
    Filed: May 11, 2007
    Publication date: January 14, 2010
    Applicant: PHARMA MAR, S.A.
    Inventor: Yusri Ali Elsayed
  • Effective Antitumor Treatments
    Publication number: 20090324744
    Abstract: ET-743 is used in the preparation of a medicament for an effective treatment of a tumour by combination therapy employing ET-743 with another drug.
    Type: Application
    Filed: September 2, 2009
    Publication date: December 31, 2009
    Applicant: PHARMA MAR, S.A.
    Inventors: Naoto Takahashi, Steve Weitman, Maurizio D'incalci, Glynn Thomas Faircloth, Rafaella Giavazzi, Andreas Gescher
  • APLIDINE TREATMENT OF CANCERS
    Publication number: 20090298752
    Abstract: Aplidine demonstrates considerable promise in phase (I) clinical trials for treatment of tumors, and various dosing regimes are given. Tumor reduction has been observed in several tumor types including renal carcinoma, colorectal cancer, lung carcinoid, medullary thyroid carcinomas and melanoma. It has also been found that aplidine has a role in inhibiting angiogenesis, complementing the anti-tumor activity.
    Type: Application
    Filed: December 23, 2008
    Publication date: December 3, 2009
    Applicant: PHARMA MAR, S.A.
    Inventors: Glynn Thomas Faircloth, Luis Paz-Ares, Chris Twelves
  • Combination of ET-743 and a 5-fluorouracil pro-drug for cancer treatment
    Patent number: 7622458
    Abstract: Methods of treating a human body for cancer are provided. In one aspect, a therapeutic amount of capecitabine is administered in combination with ET-743 in a dose range between 0.75 and 1.4 mg/m2 for Et-743. In a related aspect, an effective therapeutic amount of ET-743 is administered in combination with capecitabine in a dose range between 1500 to 2500 mg/m/day for capecitabine.
    Type: Grant
    Filed: November 15, 2004
    Date of Patent: November 24, 2009
    Assignee: Pharma Mar, S.A.U.
    Inventor: Mary Ellen Rybak
  • ANTITUMORAL TREATMENTS
    Publication number: 20090246168
    Abstract: The present invention relates to combinations of aplidine or aplidine analogues with other antitumoral agents, and the use of these combinations in the treatment of cancer, in particular in the treatment of lung cancer, breast cancer, colon cancer, prostate cancer, renal cancer, melanoma, multiple myeloma, leukemia and lymphoma.
    Type: Application
    Filed: February 28, 2007
    Publication date: October 1, 2009
    Applicant: PHARMA MAR, S.A.
    Inventors: Glynn Thomas Faircloth, Pablo Manuel Aviles Marin, Doreen LePage, Jesus San Miguel Izquierdo, Atanasio Pandiella
  • Antitumoral Treatments
    Publication number: 20090227490
    Abstract: Aplidine and aplidine analogues are of use for the treatment of cancer, in particular in the treatment of leukemias and lymphomas, especially in combination therapies.
    Type: Application
    Filed: April 30, 2009
    Publication date: September 10, 2009
    Applicant: Pharma Mar, S.A.U.
    Inventors: Joseph R. Bertino, Debabrata Barnejee, Saydam Guray, Jose Jimeno, Glynn Thomas Faircloth